October 23, 2026 · Science · Supplements · DHA
A two-year randomized trial shows that high-dose docosahexaenoic acid (DHA) crosses into the central nervous system without producing any measurable improvement in cognitive performance or brain structure. Delivering fatty acids into the central nervous system does not automatically protect cognitive function in older adults.
The study evaluated adults aged 55 to 80 years who had risk factors for dementia and low baseline fish consumption. While the primary outcome confirmed biochemical delivery into cerebrospinal fluid, secondary cognitive testing and brain imaging showed no benefit over placebo.
Two Distinct Results in Central Target Engagement and Cognition
The phase IIa trial separated central nervous system target engagement from downstream cognitive protection. Researchers at the Keck School of Medicine of the University of Southern California evaluated 365 participants across 24 months of treatment. One group received 2 grams daily of DHA, while the control group received an identical placebo.
The trial successfully met its primary biochemical endpoint. At six months, the cerebrospinal fluid DHA-to-arachidonic-acid ratio rose by 0.17 with a 95 percent confidence interval of 0.15 to 0.18 in the DHA group. The placebo group changed by -0.02 with a 95 percent confidence interval of -0.04 to -0.0004. This established a statistically significant difference of 0.19 with a 95 percent confidence interval of 0.16 to 0.21 (p < 0.0001).
Target engagement did not translate into clinical efficacy. Over 24 months, exploratory cognitive assessments and neuroimaging revealed no treatment differences between the DHA and placebo groups. Delivery into the central nervous system was achieved, yet cognitive performance and brain volumes remained unaltered.
| Outcome Measure | DHA Group (2 g Daily) | Placebo Group | Statistical Finding |
|---|---|---|---|
| 6-Month CSF DHA/AA Ratio Change | +0.17 (95% CI 0.15 to 0.18) | -0.02 (95% CI -0.04 to -0.0004) | Difference of 0.19 (p < 0.0001), endpoint met |
| 24-Month Cognitive Trajectory | No treatment difference | Reference trajectory | Secondary outcome showed no cognitive divergence |
| 24-Month Brain Volume Changes | No treatment difference | Reference trajectory | Neuroimaging showed no divergence |
Trial Population and Low Baseline Dietary Intake Criteria
The low-intake entry criterion put the supplement in front of the people with the most room to gain. Investigators screened 739 candidates and randomized 365 individuals between September 2018 and May 2024 under trial registration NCT03613844. Eligible participants were aged 55 to 80 years, had no dementia at baseline, consumed under 200 milligrams of dietary DHA daily, and carried at least one dementia risk factor.
The randomized cohort averaged 66.4 years of age with a standard deviation of 5.7 years. Women comprised 58 percent of the group, with 210 female participants enrolled. Hispanic participants accounted for 39 percent of the cohort, representing 142 individuals. The study stratified 181 participants into a lumbar puncture arm and 184 into a non-puncture arm.
Because these participants began with low dietary intake, the null cognitive result is harder to explain away than a null in well-fed eaters.
Target Engagement Across APOE e4 Genetic Risk Groups
Biochemical uptake of DHA into the central nervous system occurred independently of APOE e4 carrier status. Apolipoprotein E epsilon 4 (APOE e4) is a recognized genetic risk factor for Alzheimer disease. Carriers exhibit altered omega-3 metabolism. The trial addressed the carrier-specific uptake hypothesis that e4 carriers fail to get DHA into the brain.
The trial enrolled 173 APOE e4 carriers, representing 47 percent of the randomized cohort. Randomization was stratified by carrier status to assess uptake differences directly. Target engagement in cerebrospinal fluid remained comparable between carriers and non-carriers, yielding an interaction p-value of 0.71.
The finding demonstrates that impaired uptake into the central nervous system is not what occurred in carriers. Delivery was not the bottleneck, leading authors to suggest prioritizing brain DHA metabolism in future research.
Comparison With the 2010 Alzheimer Disease Trial
The same 2-gram dose had already returned a null cognitive result in people who already had Alzheimer disease. In a 2010 clinical trial conducted by the Alzheimer's Disease Cooperative Study, researchers administered 2 grams daily of algal DHA or placebo to 402 individuals with mild to moderate Alzheimer disease across 18 months.
The 2010 study showed no clinical or anatomical benefits. Cognitive scores on the Alzheimer's Disease Assessment Scale cognitive subscale increased by 7.98 points in the DHA group and 8.27 points in the placebo group (p = 0.41). Clinical Dementia Rating sum of boxes scores worsened by 2.87 points on DHA compared to 2.93 points on placebo (p = 0.68). In the 102-patient imaging subset, annual brain volume decline reached 1.32 percent on DHA and 1.29 percent on placebo (p = 0.79).
The 2026 findings expand this evidence base. The new trial delivered the same 2-gram dose years prior to dementia onset and verified central uptake, yet the intervention still yielded null cognitive results.
| Trial Parameter | 2010 ADCS Alzheimer Trial | 2026 eBioMedicine Prevention Trial |
|---|---|---|
| Study Population | 402 adults with mild to moderate Alzheimer disease | 365 adults without dementia at elevated risk |
| Daily Intervention | 2 grams per day algal DHA | 2 grams per day DHA |
| Study Duration | 18 months of treatment | 24 months of treatment |
| Cerebrospinal Uptake | Not measured in primary protocol | Confirmed (CSF DHA/AA ratio rose 0.17, p < 0.0001) |
| Cognitive Finding | ADAS-cog: 7.98 vs 8.27 points (p = 0.41), null | Exploratory cognitive measures showed no treatment difference |
| Volumetric Brain Imaging | 1.32% vs 1.29% annual decline (p = 0.79), null | No treatment differences in brain volumes over 24 months |
Methodological Constraints and the Impact of Participant Dropout
High participant attrition during the follow-up window weakens the statistical certainty of the secondary cognitive outcomes. Across the 24-month protocol, the trial recorded an overall dropout rate of 38 percent. The investigators attributed this attrition primarily to COVID-19.
The study design focused on a short-term biochemical primary endpoint rather than long-term clinical endpoints. Power calculations were structured around the 6-month cerebrospinal fluid ratio change among participants consenting to lumbar punctures. The trial was not powered for a 24-month cognitive endpoint.
Secondary findings from smaller trials require cautious interpretation. While the primary biochemical result met its statistical threshold, losing more than one-third of participants limits definitive conclusions about subtle cognitive changes. Funding was provided by the National Institute on Aging under award R01AG057684 and the Alzheimer's Drug Discovery Foundation under award GC-201711-2014197.
Observational Cognitive Evidence Versus Randomized Trial Data
A prevention trial did not reproduce the cognitive protection suggested by earlier observational surveys. As reviewed in our analysis of trial evidence for fish oil supplements, long-chain omega-3 fatty acids reliably reduce circulating triglycerides by roughly 15 percent, while cognitive preservation findings remain largely null. An observational review of 33 studies summarized by the National Center for Complementary and Integrative Health suggested that higher intake correlated with slower cognitive decline in healthy older adults.
The trial published in eBioMedicine tested that hypothesis directly. The investigators enrolled healthy older adults with low baseline intake, the group with the most room to gain, and confirmed that 2 grams daily reached the central nervous system. Even with verified delivery, cognitive trajectories over two years did not diverge from placebo.
The trial authors concluded that future research should prioritize investigating brain DHA metabolism rather than conducting further large-scale supplementation trials. For consumers evaluating commercial capsules, purchasing supplements specifically to prevent memory decline is not supported by these clinical findings. Neither trial tested eating fish as food.
Unresolved Hypotheses on Dietary Context and Formulation
The clinical trial evaluated isolated docosahexaenoic acid rather than whole-dietary patterns or multi-nutrient combinations. In comments reported by ScienceDaily, the lead investigator noted that omega-3 fatty acids might require the broader nutritional context of a Mediterranean-style diet to support brain health. That hypothesis represents an investigational theory rather than a finding generated by this trial.
The study did not assess alternative dosages or extended timeframes. Whether a dose other than 2 grams daily or treatment beyond 24 months would alter cognitive decline remains untested in this cohort. The trial record also did not report specific cognitive test scores or numeric brain volume measurements.
Adverse events were comparable between the active and control arms. No serious adverse events were attributed to the 2-gram daily DHA regimen.
Biomarker Testing and Genetic Risk Markers
Biomarker monitoring provides objective insight into systemic fatty acid absorption without answering clinical cognitive questions. An omega-3 index test provides an omega-3 blood measurement.
Genetic risk assessment requires separate clinical interpretation. Individuals evaluating inherited risk can review our analysis of an APOE e4 gene test. Readers can also consult our guide to homocysteine and dementia risk.
Anyone reviewing their supplement regimen should consult a licensed physician rather than modifying their intake based on marketing claims.
Some links on this page are referral links.
Sources
- Yassine H.N., Pour S.G., Juarez M., et al., "CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial," eBioMedicine 2026;129:106316, DOI 10.1016/j.ebiom.2026.106316 (PubMed record 42315445, accessed October 23, 2026). Trial registration NCT03613844.
- Quinn J.F., Raman R., Thomas R.G., et al., "Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial," JAMA 2010 (PubMed record 21045096, accessed October 23, 2026).
- "Millions take fish oil for brain health. A two-year study found no benefit," ScienceDaily, October 20, 2026 (institutional release accompanying the trial).
Frequently Asked Questions
Does fish oil improve memory?
Clinical trials indicate that fish oil supplements do not improve memory in older adults. In a 2026 randomized controlled trial published in eBioMedicine, researchers administered 2 grams daily of DHA to 365 adults aged 55 to 80 years with low baseline fish intake. While the supplement successfully raised the cerebrospinal fluid DHA-to-arachidonic-acid ratio by 0.17 compared to -0.02 on placebo, cognitive performance and brain volume showed no differences across 24 months. These results match earlier trials showing no cognitive benefit in patients with diagnosed dementia.
Does omega 3 reduce dementia risk?
Current randomized clinical trial data do not show that omega-3 supplements reduce dementia risk. The 2026 phase IIa trial enrolled 365 non-demented older adults who had low dietary omega-3 intake and at least one risk factor for dementia. Although 47 percent carried the high-risk APOE e4 allele and biochemical delivery into the central nervous system was achieved, 24 months of supplementation produced no divergence in brain volume or cognitive trajectories compared to placebo. Those population findings are associations, and this trial was the randomised test of that association in the group it was strongest for.
Does fish oil help brain function?
DHA is the most abundant long-chain polyunsaturated fatty acid in the brain, but supplements have not improved brain function in clinical trials. In a 24-month study conducted at the Keck School of Medicine of the University of Southern California, 2 grams of daily DHA achieved verified target engagement in cerebrospinal fluid. Despite crossing into the central nervous system, the active treatment showed no measurable cognitive advantage over placebo in older adults. Supplementation achieved biochemical target engagement without altering downstream cognitive performance.
Can fish oil help brain fog?
Neither of the trials covered here evaluated fish oil supplements as a treatment for brain fog. The 2026 trial registered as NCT03613844, conducted between September 2018 and May 2024, evaluated 365 participants aged 55 to 80 years with low dietary DHA and elevated dementia risk. Out of 739 screened individuals, researchers stratified 181 participants into a lumbar puncture arm and 184 into a non-puncture arm. Neither this trial nor earlier Alzheimer trials evaluated brain fog. Funding was provided by the National Institute on Aging and the Alzheimer's Drug Discovery Foundation. Anyone experiencing persistent cognitive symptoms should seek direct clinical evaluation from a physician rather than assuming supplements address those symptoms.
Is omega 3 good for memory loss?
Omega-3 supplementation does not reverse or slow memory loss in clinical studies. In a 2010 clinical trial of 402 individuals with mild to moderate Alzheimer disease, 2 grams daily of DHA for 18 months showed no significant benefit on ADAS-cog scores (7.98 vs 8.27 points, p = 0.41) or annual brain atrophy (1.32% vs 1.29%, p = 0.79). That trial ran from November 2007 to May 2009 and assigned 60 percent of participants to DHA and 40 percent to placebo. The 2026 trial confirmed that starting supplementation years earlier in non-demented adults also failed to prevent cognitive decline or brain shrinkage.
Does fish oil cause memory loss?
Neither of these two trials reported a harm signal of this kind. In the 2026 trial conducted at the University of Southern California between September 2018 and May 2024, 365 older adults received 2 grams daily of DHA or placebo over 24 months. Dropout was 38 percent, mainly due to COVID-19. Adverse events were comparable between groups, with no serious adverse events attributed to treatment. Similarly, an 18-month trial across 51 US clinical research sites gave 2 grams daily of algal DHA to 402 individuals with mild to moderate Alzheimer disease (Mini-Mental State Examination scores 14 to 26), where 295 completed on study medication (DHA 171, placebo 124). Neither trial was designed to detect harm to memory as its endpoint; they measured central uptake, cognitive performance, and brain volume, finding no treatment divergence from placebo.
Can adults take a DHA supplement?
Decisions regarding DHA supplementation should be made in consultation with a clinician. In the 2026 trial conducted from September 2018 to May 2024, taking 2 grams of DHA daily for 24 months was tested in adults aged 55 to 80 years. Out of 739 screened individuals, 365 were randomized, including 142 Hispanic participants and 173 APOE e4 carriers. The trial demonstrated that while oral DHA crossed into cerebrospinal fluid, increasing the DHA-to-arachidonic-acid ratio by 0.17 versus -0.02 on placebo, it produced no divergence in cognitive performance or brain volumes. Whether an individual adult should take a supplement depends on personal medical indications, which require personalized clinician guidance.
Does this trial mean I should stop taking fish oil?
This trial evaluated memory and brain volume rather than cardiovascular health or systemic lipid management. High-certainty evidence from a 2020 Cochrane review of 86 trials indicates that increasing long-chain omega-3s reduces circulating triglycerides by approximately 15 percent. The 2026 trial (registration NCT03613844) specifically evaluated 2 grams daily of DHA for cognitive prevention in 365 older adults with low baseline fish intake, finding no cognitive or structural benefit over 24 months despite verified central uptake. It did not test cardiovascular endpoints. Patients taking fish oil for hypertriglyceridemia or under clinician direction should not stop or change their dosage without direct medical consultation.